3,6-bis[2-(dimethylamino)ethoxy]xanthen-9-one;hydron;dichloride

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并吡喃
• 英文名称: 3,6-bis[2-(dimethylamino)ethoxy]xanthen-9-one;hydron;dichloride
• 化学式: C21H28Cl2N2O4
• 分子量: 443.4
• InChiKey: YGPTVYNBVYFRLU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.67
• 重原子数：
  29
• 可旋转键数：
  8
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  51.2
• 氢给体数：
  2
• 氢受体数：
  6

文献信息

• Pharmaceutically active compound
  申请人：Mills Oswald Charles

  公开号：US20050239712A1

  公开（公告）日：2005-10-27

  A liver-targeting active compound having the general formula (I): wherein A is α-OH or β-OH, B is α-H or β-H, C is —H, α-OH or β-OH, or B and C together form a double bond, D is —H, α-OH or β-OH, E is —H, α-OH or β-OH, -G- is a side chain moiety, —NH-J is selected from (i) a residue of an amino group-containing active compound wherein said —NH— group is provided by said amino group of the active compound, and (ii) a residue of an active compound to which an amino group has been added wherein said —NH— group is provided by said added amino group; each of X and Y independently represents a single bond, —(CH, 2 ) z — (where z is 1 to 8), —O— or —S—; n is 0 or 1; m is 0 or 1; and p is 0 or 1; provided that, when —NH-J is (i), m is 1. A method of producing such a compound is also disclosed.

  一种具有通式（I）的以肝脏为靶点的活性化合物：其中A为α-OH或β-OH，B为α-H或β-H，C为-H、α-OH或β-OH，或B和C一起形成双键，D为-H、α-OH或β-OH，E为-H、α-OH或β-OH，-G-为侧链基团，—NH-J选择自(i)含有氨基活性化合物的残基，其中所述—NH—基团由所述活性化合物的氨基提供，和(ii)添加了氨基的活性化合物的残基，其中所述—NH—基团由所述添加的氨基提供；每个X和Y独立表示单键，—（CH,2）z—（其中z为1至8），—O—或—S—；n为0或1；m为0或1；p为0或1；但当—NH-J为(i)时，m为1。还公开了一种制备这种化合物的方法。
• Compounds for Enhancing Hypoxia Inducible Factor Activity and Methods of Use
  申请人：Ratan Rajiv R.

  公开号：US20090215687A1

  公开（公告）日：2009-08-27

  The present invention relates to methods for enhancing Hypoxia inducible factor-1 (HIF) activity in a cell by contacting the cell with any one of the following compounds: 3,6-bis[2-(dimethylamino)ethoxy]-9h-xanthen-9-onedihydrochloride, 2,8-bis[dimethylaminoacetyl]dibenzofurin dihydrochloride hydrate, tilorone analogue R-9536-DA, indoprofen, ciclopiroxolamine, tryptophan, ansindione, nabumetone, oxybendazole, albendazole, tropicamide, pramoxine hydrochloride, atenolol, mebendazole, carbetapentane citrate, monensin sodium, methoxyvone, hydroxyzine, phenazopyridine, clofoctol, ipraflavone, zomepirac, biochanin A, xylometazoline hydrochloride, fenbendazole, pirenzepine, triprolidine hydrochloride, daidzein, tripelennamine citrate, colchicines, aminopyridine, trimethoprim, helenine, hydroxyurea, amiodarone hydrochloride, clindamycin hydrochloride, sulfachlorpyridazine, mephenesin, semustine, clofivric acid, clofibrate, ibuprofen, hyoscyamime, nafcillin sodium, piperin, clidinium bromide, trioxsalen, hydralazine and HIF alpha protein fused to a carrier peptide.
• Compounds For Enhancing Hypoxia Inducible Factor Activity And Methods Of Use
  申请人：Cornell Research Foundation, Inc.

  公开号：US20150258058A1

  公开（公告）日：2015-09-17

  The present invention relates to methods for enhancing Hypoxia inducible factor-1 (HIF) activity in a cell by contacting the cell with any one of the following compounds: 3,6-bis[2-(dimethylamino)ethoxy]-9h-xanthen-9-onedihydrochloride, 2,8-bis[dimethylaminoacetyl]dibenzofurin dihydrochloride hydrate, tilorone analogue R-9536-DA, indoprofen, ciclopiroxolamine, tryptophan, ansindione, nabumetone, oxybendazole, albendazole, tropicamide, pramoxine hydrochloride, atenolol, mebendazole, carbetapentane citrate, monensin sodium, methoxyvone, hydroxyzine, phenazopyridine, clofoctol, ipraflavone, zomepirac, biochanin A, xylometazoline hydrochloride, fenbendazole, pirenzepine, triprolidine hydrochloride, daidzein, tripelennamine citrate, colchicines, aminopyridine, trimethoprim, helenine, hydroxyurea, amiodarone hydrochloride, clindamycin hydrochloride, sulfachlorpyridazine, mephenesin, semustine, clofivric acid, clofibrate, ibuprofen, hyoscyamime, nafcillin sodium, piperin, clidinium bromide, trioxsalen, hydralazine and HIF alpha protein fused to a carrier peptide.
• Hydralazine and Active Derivatives Thereof for Neuronal Cell Survival and Regeneration
  申请人：BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM

  公开号：US20190298717A1

  公开（公告）日：2019-10-03

  The present invention includes a method of protecting or treating neural cells from degeneration comprising: identifying a neural cell in need of protection from at least one of radical oxidative stress, increased mitochondrial biogenesis, decreased intracellular protein aggregation or neurofibrillary tangles, increase of at least one of cellular NAD or ATP levels, activation of autophagy, removal of protein aggregates, prevents GSK3β or Tau protein phosphorylation, or increase neuronal plasticity; and providing the neural cell with a therapeutically effective amount of a hydralazine or active bioequivalent thereof sufficient to reduce radical oxidative stress, increase mitochondrial biogenesis, decrease intracellular protein aggregation or neurofibrillary tangles, increase of at least one of cellular NAD or ATP levels, activate autophagy, remove protein aggregates, prevent GSK3β or Tau protein phosphorylation, or increase neuronal plasticity, thereby protecting the neural cells from degeneration.
• US9795587B2
  申请人：——

  公开号：US9795587B2

  公开（公告）日：2017-10-24